{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T02:15:27Z","timestamp":1714529727027},"reference-count":29,"publisher":"Wiley","issue":"S51","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":7084,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1989,12]]},"abstract":"<jats:p>In multiple myeloma (MM), low\u2010cost maintenance treatment has some attractions, since maintenance of a small tumor is usually compatible with a fairly healthy state. However, the great majority of the studies of maintenance treatment have failed to show any clinical benefit. Based on simple theoretical considerations, it is shown that in MM response duration and survival are affected primarily by the residual tumor mass after primary treatment, and by the kinetics of the tumor. Continuation of maintenance treatment is likely to have a moderate effect. The main cause of that is identified in the presence or in the development of a substantial proportion of drug\u2010resistant cells. Preliminary data suggest that only alpha\u2010interferon can be useful for maintenance, and that it can act by slowing down the kinetics of the tumor.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1989.tb01508.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T17:05:25Z","timestamp":1279472725000},"page":"145-151","source":"Crossref","is-referenced-by-count":3,"title":["Maintenance treatment of multiple myeloma"],"prefix":"10.1111","volume":"43","author":[{"given":"Michele","family":"Baccarani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"Fasola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Gallizia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(81)80010-2"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1985.tb00797.x"},{"key":"e_1_2_1_4_2","first-page":"353","volume-title":"Multiple Myeloma and other Parapro\u2010teinaemias","author":"Love EM.","year":"1986"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.V73.4.865.865","article-title":"Plasma cell myeloma \u2014 New biological insights and advances in therapy","volume":"73","author":"Barlogie B","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO;2-1"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1985.171"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900060216"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb01423.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.00045.x-i1"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900060215"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1985.tb00795.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","article-title":"Remission maintenance therapy for multiple myeloma","volume":"135","author":"Southest Oncology Group Study: Alexanian R, et al","year":"1975","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","article-title":"Unmaintained remissions in multiple myeloma","volume":"51","author":"Alexanian R","year":"1978","journal-title":"Blood"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.17"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00867.x"},{"key":"e_1_2_1_18_2","unstructured":"BoccadoroM AvvisatiG BarbuiT et al.Melphalan and Prednisone vs alternating chemotherapy (VMCP\/VBAP) in multiple myeloma: results of multicenter study M83. Proc 2nd Intern Workshop on Myeloma Houston1989."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92941-4"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V57.2.333.333","article-title":"The growth fraction of human myeloma cells","volume":"57","author":"Drewinko B","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V62.1.166.166","article-title":"Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significancy and smoldering myeloma","volume":"62","author":"Greipp PR","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb06116.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197806152982401"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07488.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.1.14"},{"issue":"5","key":"e_1_2_1_26_2","first-page":"256a","article-title":"P\u2010glycoprotein staining predicts intrinsic doxorubicin resistance in patients with myeloma and lymphoma","volume":"72","author":"Salmon SE","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V73.3.747.747","article-title":"Immuno\u2010histochemical detection and quantitation of P\u2010glycoprotein in multiple drug\u2010resistant human myeloma cells: association with level of drug resistance and drug accumulation","volume":"73","author":"Dalton WS","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_28_2","unstructured":"EpsteinJ XiaoH ObaB BarlogieB.P\u2010glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Proc 2nd Intern Workshop on Myeloma Houston1989."},{"key":"e_1_2_1_29_2","unstructured":"SalmonSE GroganTM DaltonWS.Multidrug resistance in multiple myeloma: detection correlation with in vitro chemosensitvity and in vivo reversal with verapamil. Proc 2nd Intern Workshop on Myeloma Houston1989."},{"key":"e_1_2_1_30_2","unstructured":"MandelliF AvvisatiG PetrucciMT et al.Maintenance treatment with alpha\u20102b recombinant interferon significantly improves response and survival durations of responding multiple myeloma patients. Proc 2nd Intern Workshop on Myeloma Houston1989."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1989.tb01508.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1989.tb01508.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T05:23:09Z","timestamp":1697952189000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1989.tb01508.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,12]]},"references-count":29,"journal-issue":{"issue":"S51","published-print":{"date-parts":[[1989,12]]}},"alternative-id":["10.1111\/j.1600-0609.1989.tb01508.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1989.tb01508.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,12]]}}}